C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 512-517

  Chang, Hui Hua ^a   Gean, Po Wu ^a   Chou, Chen Hsi ^a,b   Yang, Yen Kuang ^a   Tsai, Hsin Chun ^a   Lu, Ru Band ^a   Chen, Po See ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

bipolar disorder; BMI; GNB3; leptin; metabolic disturbance; valproate

Indexed keywords

CHOLESTEROL; CYTOSINE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; INSULIN; LEPTIN; THYMIDINE; TRIACYLGLYCEROL; VALPROIC ACID;

ADULT; ALLELE; ARTICLE; BIPOLAR DISORDER; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE; GENETIC RISK; GENETIC VARIABILITY; GNB3 GENE; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ALLELES; BIPOLAR DISORDER; BODY MASS INDEX; FEMALE; HETEROTRIMERIC GTP-BINDING PROTEINS; HETEROZYGOTE DETECTION; HUMANS; LEPTIN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN SUBUNITS; VALPROIC ACID; YOUNG ADULT;

EID: 77957280494     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181f03f50     Document Type: Article

References (52)

1. Chang HH, Chou CH, Chen PS, et al. High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. J Affect Disord. 2009;117: 124-129.
2. Sicras A, Rejas J, Navarro R, et al. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord. 2008;10: 607-616. (Pubitemid 352003828)
3. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008;20: 131-137.
4. Fagiolini A, Chengappa KN, Soreca I, et al. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs. 2008;22: 655-669. (Pubitemid 351950097)
5. vanWinkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. 2008;10: 342-348. (Pubitemid 351637699)
6. Kim JY, Lee HW. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia. 2007;48: 1366-1370. (Pubitemid 47063070)
7. Elmslie JL, Porter RJ, Joyce PR, et al. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust N Z J Psychiatry. 2009;43: 53-60.
8. Pylvanen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia. 2002;43: 514-517. (Pubitemid 34533707)
9. Chang HH, Yang YK, Gean PW, et al. The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord. 2010;124: 319-323. doi: 10.1016/j.jad.2009.1012.1011.
10. Gergerlioglu HS, Savas HA, Celik A, et al. Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients. Neuropsychobiology. 2006;53: 108-112.
11. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2007;98: 247-252. (Pubitemid 46151723)
12. Yumru M, Savaz E, Gergerlioglu HS, et al. The relationship of metabolic syndrome, serum leptin levels and treatment in bipolar disorder. Bull Clin Psychopharmacol. 2008;18: 79-83. (Pubitemid 351919645)
13. Pylvanen V, Pakarinen A, Knip M, et al. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 2006;8: 643-648.
14. SiffertW, Rosskopf D, Siffert G, et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet. 1998;18: 45-48. (Pubitemid 28027877)
15. Siffert W. G protein beta 3 subunit 825T allele, hypertension, obesity, and diabetic nephropathy. Nephrol Dial Transplant. 2000;15: 1298-1306.
16. Kopf D, Cheng LS, Blandau P, et al. Association of insulin sensitivity and glucose tolerance with the c.825C9T variant of the G protein beta-3 subunit gene. J Diabetes Complications. 2008;22: 205-209. (Pubitemid 351539059)
17. Casiglia E, Tikhonoff V, Caffi S, et al. Effects of the C825T polymorphism of the GNB3 gene on body adiposity and blood pressure in fertile and menopausal women: a population-based study. J Hypertens. 2008;26: 238-243.
18. Hayakawa T, Takamura T, Abe T, et al. Association of the C825T polymorphism of the G-protein beta3 subunit gene with hypertension, obesity, hyperlipidemia, insulin resistance, diabetes, diabetic complications, and diabetic therapies among Japanese. Metabolism. 2007;56: 44-48. (Pubitemid 44855011)
19. Danoviz ME, Pereira AC, Mill JG, et al. Hypertension, obesity and GNB 3 gene variants. Clin Exp Pharmacol Physiol. 2006;33: 248-252.
20. Brand E, Wang JG, Herrmann SM, et al. An epidemiological study of blood pressure and metabolic phenotypes in relation to the Gbeta3 C825T polymorphism. J Hypertens. 2003;21: 729-737. (Pubitemid 36549668)
21. Meirhaeghe A, Cottel D, Amouyel P, et al. Lack of association between certain candidate gene polymorphisms and the metabolic syndrome. Mol Genet Metab. 2005;86: 293-299. (Pubitemid 41412187)
22. Souza RP, De Luca V, Muscettola G, et al. Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32: 1848-1853.
23. Chen G, Hasanat KA, Bebchuk JM, et al. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med. 1999;61: 599-617. (Pubitemid 29455084)
24. Hahn CG, Umapathy, Wang HY, et al. Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J Psychiatr Res. 2005;39: 355-363.
25. Martini JS, Raake P, Vinge LE, et al. Uncovering G proteinYcoupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A. 2008;105: 12457-12462.
26. Beaulieu JM, Caron MG. Beta-arrestin goes nuclear. Cell. 2005;123: 755-757.
27. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IVand ICD-10. J Clin Psychiatry. 1998;59(suppl 20): 22-33. (Pubitemid 29001829)
28. Hong CJ, Chen TJ, Yu YW, et al. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006;6: 27-33. (Pubitemid 43118308)
29. Wang YC, Bai YM, Chen JY, et al. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet Genomics. 2005;15: 743-748.
30. Hauner H, Meier M, Jockel KH, et al. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics. 2003;13: 453-459. (Pubitemid 37034587)
31. Kato M, Wakeno M, Okugawa G, et al. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32: 1041-1044. (Pubitemid 351609242)
32. Wilkie MJ, Smith D, Reid IC, et al. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics. 2007;17: 207-215. (Pubitemid 46668005)
33. Lee HJ, Cha JH, Ham BJ, et al. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J. 2004;4: 29-33.
34. Willeit M, Praschak-Rieder N, Zill P, et al. C825T polymorphism in the G protein beta3-subunit gene is associated with seasonal affective disorder. Biol Psychiatry. 2003;54: 682-686. (Pubitemid 37281383)
35. Beaulieu JM, Marion S, Rodriguiz RM, et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008;132: 125-136.
36. Stockli J, James DE. Insulin action under arrestin. Cell Metab. 2009;9: 213-214.
37. Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166: 591-598.
38. Reagan LP. Insulin signaling effects on memory and mood. Curr Opin Pharmacol. 2007;7: 633-637.
39. Rosskopf D, Manthey I, Siffert W. Identification and ethnic distribution of major haplotypes in the gene GNB3 encoding the G-protein beta3 subunit. Pharmacogenetics. 2002;12: 209-220. (Pubitemid 34596785)
40. Siffert W, Forster P, Jockel KH, et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol. 1999;10: 1921-1930. (Pubitemid 29402513)
41. Huang X, Ju Z, Song Y, et al. Lack of association between the G protein beta3 subunit gene and essential hypertension in Chinese: a case-control and a family-based study. J Mol Med. 2003;81: 729-735. (Pubitemid 37491599)
42. Brand E, Herrmann SM, Nicaud V, et al. The 825C/T polymorphism of the G-protein subunit beta3 is not related to hypertension. Hypertension. 1999;33: 1175-1178. (Pubitemid 29230969)
43. Dong Y, Zhu H, Sagnella GA, et al. Association between the C825T polymorphism of the G protein beta3-subunit gene and hypertension in blacks. Hypertension. 1999;34: 1193-1196. (Pubitemid 30002381)
44. Saller B, Nemesszeghy P, Mann K, et al. Glucose and lipid metabolism in young lean normotensive males with the G protein beta3 825T-allele. Eur J Med Res. 2003;8: 91-97.
45. Kiani JG, Saeed M, Parvez SH, et al. Association of G-protein beta-3 subunit gene (GNB3) T825 allele with Type II diabetes. Neuro Endocrinol Lett. 2005;26: 87-88. (Pubitemid 40674208)
46. Ranade K, Wu KD, Risch N, et al. Genetic variation in aldosterone synthase predicts plasma glucose levels. Proc Natl Acad Sci U S A. 2001;98: 13219-13224. (Pubitemid 33051343)
47. Lan TH, Loh EW, Wu MS, et al. Performance of a neuro-fuzzy model in predicting weight changes of chronic schizophrenic patients exposed to antipsychotics. Mol Psychiatry. 2008;13: 1129-1137.
48. Lin E, Chen PS, Chang HH, et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33: 1167-1172.
49. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004;109: 433-438. (Pubitemid 38133916)
50. Blalock EM, Grondin R, Chen KC, et al. Aging-related gene expression in hippocampus proper compared with dentate gyrus is selectively associated with metabolic syndrome variables in rhesus monkeys. J Neurosci. 2010;30: 6058-6071.
51. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology. 2002;46: 176-179. (Pubitemid 36173364)
52. Verrotti A, la Torre R, Trotta D, et al. Valproate-induced insulin resistance and obesity in children. Horm Res. 2009;71: 125-131.